Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7508 versus apixaban for stroke and systemic embolism prevention in atrial fibrillation
NL-OMON61665Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Cenvacibart with Apixaban (2 arms). Primary endpoints: Time to first occurrence of stroke or systemic embolism and Time to first occurrence of clinically relevant bleeding. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
cenvacibartapixaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NL-OMON61665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61665.